Nuvation Bio (NUVB) H.C. Wainwright 27th Annual Global Investment Conference summary

Product and clinical pipeline highlights

• IBTROZI, a ROS1 TKI, launched with an 89% response rate and 46-month PFS in first-line setting, achieving rapid early uptake with 70 prescriptions in seven weeks.

• Market opportunity for IBTROZI estimated at $4–5 billion annually by year four, driven by long duration of response and expanded detection via RNA testing.

• TRUST-I/II trials show nearly 90% first-line and 62% second-line response rates, with robust 66% intracranial response in second-line patients.

• IDH1 inhibitor safusidenib shows a 33% response rate in low-grade glioma and 17% in high-grade, with some complete remissions lasting years; pivotal studies underway.

• DDC platform enables small molecule drug conjugates; NUV-1511 in early trials across five indications, with initial data expected later this year.

Competitive landscape and market dynamics

• IBTROZI outperformed repotrectinib in early launch metrics and is supported by recent NCCN guideline changes favoring ROS1 agents.

• Nuvalent's trial design excludes patients with secondary oncogenic drivers, unlike the real-world approach in IBTROZI studies.

• Nuvalent's efficacy claims are based on limited patient data, with only three patients reaching 18 months in their PFS analysis.

• Safety profiles between IBTROZI and competitors are similar, with low discontinuation rates and manageable adverse events.

• Market tailwinds include increased NGS testing and guideline changes, supporting broader adoption of targeted therapies.

Financial position and strategic outlook

• Cash reserves at end of Q2 were approximately $600 million, with additional milestone and royalty payments expected.

• Operational runway is strong, with sufficient funds to reach profitability and support ongoing commercial and R&D activities.

• Commercial spend and sales force investments are reflected in Q2, serving as a proxy for future expenditure.

• Strategic focus includes expanding the DDC platform and advancing pivotal studies in glioma.

• Ongoing evaluation of pipeline assets for broader immuno-oncology applications.